Hørsholm,
Although the mechanism of action may differ, we have demonstrated that altering the surface properties of select vaccine candidates can enhance the immune response in animals to levels previously achieved only through nanoparticle presentation of the vaccine protein. We are continuing to investigate both the underlying mechanisms and other proof-of-concept applications of glycomodification.
Dr.
"We are now witnessing the outcomes of our continuous efforts to enhance and expand the capabilities of our proprietary platform. Through our R&D, we have succeeded in improving not only the quantity but also the features of proteins expressed for vaccine purposes. This patent is a significant testament to the team's dedication, and I am excited to see it come to fruition"
About glycoengineering in Drosophila S2 cells and the prospects
By modifying specific biochemical pathways in our Drosophila S2 cell lines, we enable them to alter the surface properties of the proteins they produce. These modifications can significantly enhance the immune response to a protein, making the resulting vaccine much more effective while also reducing production costs. We are continually developing these GlycoX-S2 cell lines to further refine the ExpreS2™ system's full potential for creating novel vaccines. In
Certified Adviser
The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Email: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with
https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-u-s--patent-issue-notification-for-glyco-engineered-immunization-antigens,c4010740
https://mb.cision.com/Main/14402/4010740/2899363.pdf
(c) 2024 Cision. All rights reserved., source